News

Isaacs and Bellini walk through the newly released Preexisting Diabetes in Pregnancy guidelines, discussing each of the 10 recommendations.

Sanyal describes the growing burden of SLD and its connection to other major chronic diseases, underscoring the need for better recognition and prevention efforts.

This study evaluated a set of key AI outputs: skin tone representation and diagnostic accuracy of generated dermatologic diseases.

Post-COVID CT guidance favors low-dose imaging, clear terms, and precise timing.

Positive topline results showed obefazimod met its primary endpoint for clinical remission at week 8 in the 50 mg dose cohort in ABECT-1 and ABECT-2.

In children with mild immediate or delayed reactions, direct drug provocation testing may eliminate the need for painful skin tests, according to new data from Türkiye.

This episode of Lungcast features a discussion on the connection between diet, gut microbiome and lung health.

Kuter describes several studies investigating aspects of rilzabrutinib which were presented at the ISTH 2025 Congress.

Findings showed GLP-1 RAs reduced the risk of overall dementia, particularly Alzheimer’s disease and non-vascular dementias, compared with metformin.

Fudim discusses his experiences in prescribing GLP-1 receptor agonists, as well as his opinions regarding remote patient monitoring.

The National Institute for Health and Care Excellence endorses betula verrucosa for long-term relief from severe birch tree allergies, such as allergic rhinitis or conjunctivitis.

Study findings showed IBS patients with self-perceived gluten sensitivity reacted similarly to gluten, wheat, and sham challenges.

This case–control study compared sleep quality, risk of obstructive sleep apnoea, and quality of life between those with psoriasis and healthy controls.

Genentech reveals mixed results for astegolimab in COPD trials, highlighting challenges in treatment options for this serious respiratory disease.

This interview with Saakshi Khattri, MD, highlights recent findings on deucravacitinib as an oral therapy for patients living with psoriatic arthritis (PsA).

Presented at ENDO 2025, crinecerfont exhibited sustained androgen reduction when combined with glucocorticoids.

A new study showed that cashew-induced anaphylaxis mostly affects children under 5 years, often from tiny amounts that are under a teaspoon.

In CKD patients with COVID-19, prior vaccination significantly reduced risks of major adverse kidney events and mortality, especially with ≥ 3 doses.

Nearly 13 million people received DAA treatment in the last 10 years, representing 21% of the starting 62 million people with chronic HCV and 30% of the target population.

Isaacs and Bellini discuss the highlights of the Endocrine Society’s annual meeting, from upcoming treatments to public education.

Patients with hereditary angioedema who switched to donidalorsen saw significantly fewer attacks and improved disease control. The FDA decision expected in August 2025.

The announcement of this NDA submission to the FDA highlights icotrokinra, a first-in-class investigational targeted oral peptide for plaque psoriasis.

In this interview segment, Hamade highlights the potential benefits of an oral drug like deucravacitinib in psoriasis and psoriatic arthritis.

A 2-step direct amoxicillin challenge safely ruled out penicillin allergy in low-risk pregnant patients, offering a faster alternative to skin testing.

An audio recap of the top 5 stories in healthcare news from the week of 07/07-07/13.

This analysis examined the connection between atopic dermatitis severity and frequency of flares, along with which variables potentially predict flares.

Psychiatrists at the 2025 So Cal Psych Conference shared evidence-based tools and therapies to improve mental health outcomes for new mothers.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and designations as well as new clinical trial data, in this week's essential news roundup.